CAR T-cell therapies offer an exciting new way to treat cancer. The NRC is working with academic, clinical and industry researchers to develop these cutting-edge therapies—and focusing on making them accessible to Canadian patients.
Overview of the NRC's work on CAR T-cell therapies
Building on decades of experience developing vaccines and other biologics, our Human Health Therapeutics researchers are combining knowledge of fundamental biology of immune cells with expertise in the production of antibodies to create novel made-in-Canada CAR T-cell therapies.
CAR T-cell therapy for blood cancers
In collaboration with partners across Canada, our researchers are developing and testing an innovative CAR T-cell therapy that offers a new approach to treating certain blood cancers.
Features
CAR T-cell therapy for solid tumor cancers
CAR T-cell therapy has been successful in treating blood cancers, but using this therapy to treat solid tumors remains challenging. Our researchers are exploring ways to help CAR-T cells find and attack solid tumor cancers, while ensuring they work well in these difficult environments.